Commerzbank Aktiengesellschaft FI Sells 80,413 Shares of Pfizer Inc. $PFE

Posted by Stanley Muller on Jul 21st, 2026

Commerzbank Aktiengesellschaft FI lessened its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 15.3% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 444,413 shares of the biopharmaceutical company’s stock after selling 80,413 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Pfizer were worth $12,479,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Legacy Wealth Managment LLC ID lifted its stake in Pfizer by 46.6% in the 1st quarter. Legacy Wealth Managment LLC ID now owns 2,566 shares of the biopharmaceutical company’s stock valued at $72,000 after purchasing an additional 816 shares during the last quarter. AlTi Global Inc. increased its position in Pfizer by 5.9% during the first quarter. AlTi Global Inc. now owns 39,768 shares of the biopharmaceutical company’s stock worth $1,117,000 after buying an additional 2,231 shares during the last quarter. Allen Holding Inc. NY increased its position in Pfizer by 31.6% during the first quarter. Allen Holding Inc. NY now owns 2,000,000 shares of the biopharmaceutical company’s stock worth $56,160,000 after buying an additional 480,200 shares during the last quarter. Commonwealth Financial Services LLC raised its stake in Pfizer by 9.5% in the first quarter. Commonwealth Financial Services LLC now owns 42,617 shares of the biopharmaceutical company’s stock valued at $1,197,000 after buying an additional 3,690 shares during the period. Finally, Meeder Asset Management Inc. lifted its position in shares of Pfizer by 130.9% in the first quarter. Meeder Asset Management Inc. now owns 2,789 shares of the biopharmaceutical company’s stock valued at $78,000 after buying an additional 1,581 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

Negative Sentiment: Pfizer faces expanded international patent lawsuits over its COVID-19 vaccine, with Arbutus Biopharma and Genevant Sciences seeking damages and possible injunctions. That raises legal and operational uncertainty for the company. Pfizer (PFE) Faces New International Patent Lawsuits Over Covid 19 Vaccine
Negative Sentiment: Pfizer was noted as falling more than the broader market in the latest session, reinforcing near-term weakness in the stock. Pfizer (PFE) Falls More Steeply Than Broader Market: What Investors Need to Know
Negative Sentiment: Erste Group Bank lowered earnings estimates for Pfizer, which can signal softer expectations for future profitability. Erste Group Bank Decreases Earnings Estimates for Pfizer
Neutral Sentiment: Pfizer has been drawing heavy user interest on Zacks, but the coverage is largely a stock-screening/discussion piece rather than a new company-specific catalyst. Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
Neutral Sentiment: Separate articles highlighted Pfizer as a possible contender in the $100 billion weight-loss market and as a cheap income stock, which supports the bullish long-term narrative but does not change near-term fundamentals on its own. Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market? Looking for Cheap Income Stocks? Why Pfizer Belongs on Your Shortlist Right Now

Pfizer Price Performance

Pfizer stock opened at $24.75 on Tuesday. The firm has a market cap of $141.04 billion, a PE ratio of 18.89 and a beta of 0.35. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The stock’s fifty day moving average price is $25.19 and its two-hundred day moving average price is $26.18. Pfizer Inc. has a one year low of $23.11 and a one year high of $28.75.

Pfizer (NYSE:PFE – Get Free Report) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. During the same period in the prior year, the company posted $0.92 EPS. The company’s revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, research analysts expect that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio is presently 131.30%.

Wall Street Analyst Weigh In

PFE has been the subject of several research analyst reports. Morgan Stanley lifted their target price on Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. BMO Capital Markets cut their price target on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Wolfe Research reaffirmed an “underperform” rating and set a $26.00 price objective on shares of Pfizer in a research report on Thursday, May 14th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a report on Monday, July 6th. Finally, Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective on the stock in a research report on Tuesday, June 9th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $28.50.

Check Out Our Latest Stock Analysis on Pfizer

Pfizer Company Profile

(Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.